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Binding inhibitors restore furosemide potency in tubule fluid
containing albumin
KENT A. KIRCHNER, JAMES R. VOELKER, and D. CL&IG BRATER
Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi and Department of Medicine, Indiana University
School of Medicine, Indianapolis, Indiana
Binding inhibitors restore furosemide potency in tubule fluid containing
albumin. We have previously suggested that albumin in tubule fluid at
concentrations found in the nephrotic syndrome (NS) binds furosemide,
thereby diminishing diuretic effect. This mechanism may contribute to
diuretic resistance in NS. If this hypothesis is correct, displacement of
albumin from furosemide should restore diuretic response in tubule
fluid containing albumin. To test this supposition, in vivo loop micro-
perfusion was performed in rats using perfusates containing 6 sM
furosemide in the presence or absence of 3.8 LM albumin, or furosemide
and albumin to which 12 iLM warfarin or 5.4 mM sulfisoxazole had been
added. These drugs are inhibitors of albumin-furosemide binding in
plasma. Albumin in the perfusate impaired furosemide effect on loop
chloride reabsorption (1248 59 vs. 886 65 pEq/min; P < 0.05).
Addition of warfarin or sulfisoxazole to perfusate containing albumin
normalized furosemide's effect. Neither drug affected furosemide re-
sponse in the absence of albumin. Dansylsarcosine, a probe that binds
albumin at a different site than furosemide, failed to normalize furo-
semide response in albumin perfusates. These data suggest that albumin
in tubule fluid reduces diuretic response through a diminution in the free
furosemide concentration. In as much as this mechanism contributes to
diuretic resistance observed clinically in NS, displacement of furo-
semide from albumin binding sites may be a therapeutic strategy
warranting study.
An attenuated response to loop diuretics is a frequent obser-
vation in patients with nephrotic range proteinuria [1, 2]. Dose
response analysis comparing urinary excretions rates of diuretic
and sodium demonstrate that nephrotic patients are less respon-
sive to a given dose of drug than healthy subjects [2]. Thus,
tubular resistance to the natriuretic effect of 1oop diuretics has
been proposed to explain the blunted response. The mechanism
of this tubular resistance is unknown. A contributing mecha-
nism for diuretic resistance in patients with nephrotic syndrome
(NS) may relate to the fact that furosemide, which is highly
bound to albumin in serum, may also bind to albumin in the
urine. As the protein bound fraction of a drug is considered to
be inactive, furosemide binding to urinary albumin would
therefore decrease response by reducing the unbound (that is,
active) drug concentration at its site of action in the thick
ascending limb of Henle's loop (TALH). In support of this
hypothesis, we have shown that the addition of albumin to
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tubule fluid perfusing Henle's loop markedly reduces the ability
of furosemide to inhibit 1oop segment chloride reabsorption [31.
This effect appears to occur through a specific interaction
between albumin and furosemide in that albumin alone has no
effect on loop segment chloride transport, and other proteins
such as IgG do not blunt furosemide's response. Although the
results of that study are consistent with a reduction in concen-
tration of free furosemide in tubule fluid, the study design did
not allow for a direct examination of this putative mechanism.
In an effort to more specifically study the influence of protein
binding in renal tubule fluid on diuretic response, we conducted
a series of experiments designed to displace furosemide from its
albumin binding site. An improvement in diuretic response
following these maneuvers would further support the correct-
ness of our hypothesis and might also lead to future therapeutic
strategies to improve diuretic responsiveness in this disorder.
In in vitro systems, albumin has been found to contain at least
three specific and discrete binding sites for drugs [4]. The extent
of a drug's binding to albumin can be modified by the presence
of another xenobiotic or endogenous substance which competes
for binding at the same site. We reasoned that if the attenuated
response to furosemide observed in albumin containing perfu-
sates is due to albumin-furosemide binding, then drugs that
displace furosemide would thereby restore the diuretic's po-
tency. In contrast, compounds binding at albumin sites that do
not affect furosemide's binding should not alter the diuretic
response. The current study tested this hypothesis using in vivo
loop segment microperfusion techniques to ensure precise
delivery of drugs and solutes to the loop segment.
Methods
Male Sprague-Dawley rats maintained on standard rat chow
and ad libitum fluids were anesthetized with mactin (100
mg/kg/body wt i.p.) and prepared for micropuncture. The
specific preparative surgical procedures used in our laboratory
have been described previously [3, 5]. Following a 40-minute
surgical recovery period, in vivo loop segment microperfusion
was performed over a 90-minute experimental period. Blood
was sampled periodically for determination of inulin, sodium
and chloride concentrations. A timed urine sample was col-
lected for determination of inulin and sodium concentrations
from the experimental kidney. At the conclusion of study, the
kidneys were removed and weighed.
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The microperfusion technique was performed as follows: A
pipette filled with FD&C green (Keystone Aniline and Chemi-
cal, Chicago, Illinois, USA) tinted nonradioactive perfusate
was inserted into a random proximal tubule and a small bolus
injected to identify both latest surface proximal and earliest
surface distal segments of that nephron. The loop segment
studied included a short terminal segment of a proximal convo-
luted tubule, the proximal straight tubule, the thin descending
limb of Henle's loop, the TALH and a short segment of the
distal convoluted tubule. A perfusion pipette attached to a
microperfusion pump (WPI Instruments, New Haven, Connect-
icut, USA) calibrated previously in vitro for 20 ni/mm was
inserted into the latest accessible proximal tubule and perfusion
of the nephron begun. The perfusate was an artificial tubule
fluid-like (ATF) solution and contained (in millirnolar) NaCI,
123; KC1, 5; MgSO4, 1; NaHCO3, 10; Na2HPO4, 1; CaCI2, 1;
urea, 4.2. Dialyzed (methoxy 3H) inulin (New England Nuclear,
Boston, Massachusetts, USA) was added to yield 100 to 150
cpm/nl. The pH was adjusted to 7.4 with 5% C02-95% 02.Next
a pipette was inserted proximal to the perfusion pipette and a
large caster oil block introduced. The tubule segment proximal
to the block was then vented and the glomerular filtration
allowed to escape onto the kidney surface. Two to three
minutes of perfusion were allowed to insure good flow. A
collection pipette filled with Sudan black stained mineral oil was
then inserted into the earliest surface distal tubule segment. An
oil block was injected and a complete timed distal tubule fluid
sample obtained.
Eleven groups of rats were studied. The first group (N =8)
served as furosemide controls. Loop segments in these animals
were perfused with ATF to which 6.0 LM furosemide (Hoechst-
Roussel Pharmaceuticals, Somerville, New Jersey, USA) had
been added. This concentration of furosemide was chosen to
approximate the concentration having a half maximal effect to
inhibit chloride reabsorption (IC50) as determined in the isolated
perfused rabbit TALH [6]. In the second group of rats (N = 7)
loop segments were perfused with the ATF furosemide perfus-
ate to which 3.8 tM human serum albumin (fat free fraction V,
Sigma Chemical Co., St. Louis, Missouri, USA) was added.
The concentration of albumin was chosen to approximate the
concentration measured at late proximal tubule puncture sites
142 to 144 hours after induction of aminonucleoside nephrosis
in the rat [7]. In the third group of rats (N = 7) loop segments
were perfused with the albumin-furosemide ATF containing
12.0 LM warfarin (Dupont Pharmaceuticals, Wilmington, Dela-
ware, USA). Warfarin is the prototypic drug that binds to the
same site on albumin as furosemide [4]. To exclude the possi-
bility that warfarin itself potentiates furosemide response, loop
segments in a fourth group of rats (N 6) were perfused with
ATF containing furosemide and warfarin but no albumin. A fifth
group of rats (N = 5) were warfarin controls. Loop segments in
these rats were perfused with ATF which contained only 12.0
jLM warfarin. In a sixth group of rats (N = 7) loop segments
were perfused with the furosemide-albumin perfusate contain-
ing 5.4 mM sulfisoxazole (Hoffman-LaRoche, Nutley, New
Jersey, USA). Sulfisoxazole binds at the same site as furo-
semide on the albumin molecule [4]. Prior unpublished work by
our laboratory indicated that displacement of furosemide from
albumin by sulfisoxazole might occur with urine concentration
of the drug that can be obtained clinically. Thus, sulfisoxazole
was chosen for study because it might prove useful in future
clinical tests of the role of intratubular binding of furosemide in
man. As with warfarin, the possibility that sulfisoxazole itself
could potentiate furosemide's response was examined in a
seventh group of rats (N = 6) where loop segments were
perfused with ATF containing furosemide and 5.4 mri sulfisox-
azole but no albumin. In an eighth group cf rats (N 6) loop
segments were perfused with the furosemide-albumin ATF to
which 12 tM dansylsarcosine (Sigma Chemical Co.) had been
added. Dansylsarcosine binds to the albumin molecule at a site
separate from that which binds furosemide [4]. The concentra-
tions of warfarin and dansylsarcosirie employed were based on
the finding that the binding constants for these drugs to their
primary site on the albumin molecule are each less than 10 sM
[4]. Dansylsarcosine, however, also binds at the furosemide site
above concentrations of approximately 40 M [4]. The concen-
tration of sulfisoxazole chosen was based on our prior work and
that by others in man showing urinary drug concentrations in
the m range following a standard size dose [8].
To provide additional evidence that albumin blunted furo-
semide's response by decreasing the unbound or pharmacolog-
ically active fraction of the drug, the effects of increasing the
concentrations of furosemide and/or albumin on loop furo-
semide response were determined in three additional groups. In
a ninth group of rats (N = 6) furosemide concentration was
increased to 60 pM in ATF containing 3,8 /SM albumin to
determine if the presumed increase in free drug concentration
would normalize diuretic response. In a tenth group of rats (N
= 5) the albumin concentration was doubled to 7.6 M in ATF
containing 60 jsM furosemide to see if diuretic response would
again be blunted. Finally an eleventh group of rats (N =6) were
controls for the larger furosemide dose. Loop segments in these
animals were perfused with ATF which contained only 60 JSM
furosemide.
Analytical techniques
The volume of tubule fluid collected from the distal tubule
was measured in constant bore glass tubing with a slide com-
parator (Gaertner Scientific, Chicago, Illinois, USA). An ali-
quot of sample was then withdrawn and the chloride concen-
tration determined using electrometric titration as previously
described [5]. Perfusate chloride was also measured for direct
comparison. The remaining volume was measured and the
sample counted for 10 minutes in a liquid scintillation counter
(Model LS7500, Beckman Instrument Co., Irvine, California,
USA) to determine 3H inulin radioactivity. Sodium concentra-
tion in serum and urine was measured by flame photometry
(Instrumentation Laboratory, Model 943, Lexington, Massa-
chusetts, USA). Inulin concentration in urine and plasma was
determined as previously described [5].
Analysis of data
Determination of the concentrations of inulin and sodium in
blood and urine and urinary flow rate permitted calculation of
whole kidney glomerular filtration rate and urinary excretion
rate of sodium according to standard expressions. In vivo
perfusate rate (PR) was calculated as:
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Table 1. Systemic and whole kidney variables in the experimental groups
MAP
mm Hg
C1,,
j.d/min/g
kidney wt
UNaV
nEqiminig
kidney wt
FEN,,
%
Na
mEqiliter
6.0 sM Furosemide
Furosemide (N = 8)
Furosemide-albumin (N = 7)
Furosemide-albumin-warfarin (N = 7)
Furosemide-warfarin (N = 6)
Furosemide-albumin-sulfisoxazole (N = 7)
Furosemide-sulfisoxazole (N = 6)
Furosemide-albumin-dansylsarcosine (N = 6)
60 M Furosemide
Furosemide(N = 6)
Furosemide-albumin (N = 6)
Furosemide-7.6 /LM albumin (N = 5)
Warfarin control (N = 5)
119 3
122 3
117 3
116 3
118 2
123 3
122 2
121 2
124 2
120 2
124 4
1040 74
986 64
968 57
940 78
1151 95
971 66
1128 65
1192 102
1250 63
998 137
1282 21!
374 197
257 115
338 88
212 119
449 217
233 97
692 359
113 28
148 31
237 116
420 199
0.21 0.09
0.16 0.06
0.24 0.07
0.15 0.07
0.24 0.11
0.18 0.09
0.40 0.20
0.07 0.02
0.08 0.02
0.13 0.05
0.21 0.10
153 1
155 2
152 2
150 2
154 2
150 4
155 3
155 3
157 1
147 1
152 3
Values are means SE. Abbreviations are: Numbers in parenthesis, number of animals studied; MAP, mean arterial pressure; Ca,, inulin
clearance; UNaV, absolute urinary sodium excretion; FEN,,, fractional sodium excretion; DNa, plasma sodium concentration.
Table 2. Loop perfusion rate, absolute and fractional loop segment fluid reabsorption
Calculated PR
ni/mm TF1,,/Perf1,,
Absolute fluid
reabsorption
ni/mm
Fractional fluid
reabsorption
6.0 M Furosemide
Furosemide (N = 8) 19.6 0.4 1.51 0.04 6.47 0.39 33.0 2.2
Furosemide-albumin (N = 7) 19.2 0.5 1.45 0.05 6.00 0.55 29.7 2.2
Furosemide-albumin-warfarin (N = 7) 18.3 0.5 1.41 0.05 5.11 0.43 27.1 2.6
Furosemide-warfarin (N = 6) 20.9 0.6 1.49 0.05 6.50 0.95 30.6 3.4
Furosemide-albumin-sulfisoxazole (N = 7) 19.0 0.4 1.48 0.04 6.26 0.45 32,0 2.0
Furosemide-sulfisoxazole (N = 6) 19.2 0,5 1.44 0.04 5.77 0.40 29.6 1.8
Furosemide-albumin-dansylsarcosine (N = 6) 19.1 0.9 1.60 0.05 7.09 0.62 36.8 1.9
60 sM Furosemide
Furosemide (N = 6) 19.1 0.3 1.36 0.03 4.71 0.34 24.5 2.3
Furosemide-albumin (N = 6) 19.6 0,4 1.43 0.05 5.75 0.56 29.2 2.8
Furosemide-7.6 iLM albumin (N 5) 20.1 0.9 1.53 0.04 6.79 0.18 34.1 1.7
Warfarin control (N = 5) 19.0 0.9 1.49 0.06 5.99 0.63 31.4 2.9
Values are means SE. Abbreviations are: PR, in vivo perfusion rate; TF1/Perf1,,, tubule fluid to perfusate inulin.
cpm2PR = CR x (ni/mm)
cpm1
where CR is the distal collection rate, and cpm1 and cpm2 are
the cpmlnl of 3H inulin in the perfusate and collected fluid,
respectively. Only perfusions having a calculated perfusion rate
between 15 and 25 nl/min were accepted for analysis. Tubular
response to furosemide was determined by calculating the
absolute amount of chloride reabsorption (AR1). This param-
eter was calculated as:
AR1 = (Perf1 x PR) — (EDCI x CR)
where Perf1 and ED1 are chloride concentrations in the
perfusate and fluid collected from the early distal tubule,
respectively. Values are expressed as mean SE. The results
from one to seven tubules (mean SE, 3.7 0.5) were used for
each rat and an "N" representing the number of rats (not
tubules) was used to calculate group means.
Analysis of variance was used to determine statistical signif-
icance. If analysis of variance indicated that a statistical signif-
icance existed, Bonferroni's modification of the f-test was used
to determine differences among groups. Statistical significance
was set at the P <0.05 level.
Results
Mean arterial pressure, inulin clearance, and absolute as well
as fractional urinary sodium excretions were not different
between any of the study groups (Table 1). Plasma sodium
concentrations were also not different between groups.
Loop segment perfusion rate determined in vivo was not
different between groups (Table 2). Neither absolute nor frac-
tional loop segment fluid reabsorption was different between
groups (Table 2). Thus, the respective solute and total furo-
semide deliveries to the loop segment were equivalent in all
groups. In agreement with our previous studies, addition of 3.8
tM albumin to the perfusion solution markedly (P < 0.05)
impaired the inhibitory effect of furosemide on loop chloride
reabsorption (Fig. 1). Loop chloride reabsorption increased
from 886 65 pEq/min in segments perfused with ATF con-
taining furosemide to 1248 59 pEq/min in loop segments
perfused with ATF containing furosemide and albumin (Fig. 1).
The addition of warfann to perfusate which contained albumin
C
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and furosemide restored loop chloride reabsorption to 851 54
pEq/min. This value was significantly less (P < 0.05) than the
amount of chloride reabsorbed by loop segments perfused with
albumin and furosemide, but not statistically different from the
amount reabsorbed by loop segments perfused by furosemide
alone. Of note, warfarin per se appeared to have no intrinsic
effect on solute transport by the ioop segment. Loop segment
chloride reabsorption was 1684 137 pEq/min during perfusion
with ATF containing 12 LM warfarin alone. This reabsorptive
rate is not different (P = NS by unpaired Student's t-test) from
the reabsorptive rate of 1375 86 pEq/min previously reported
from our laboratory during perfusion of loop segments with
ATF alone [5]. Furthermore, the addition of warfarin to perfus-
ates which contain furosemide without albumin did not alter
furosemide's effect on loop chloride reabsorption (986 81 vs.
886 65 pEqlmin; P = NS). Thus, warfarin's inhibition of
chloride transport by the 1oop segment occurred only in the
presence of furosemide and albumin.
A pattern similar to the warfarin experiments was observed
following addition of sulfisoxazole. This displacing agent also
restored responsiveness to furosemide (Fig. 1). Thus, chloride
reabsorption was significantly lower in loop segments perfused
with ATF containing the combination of furosemide, sulfisox-
azole and albumin compared to loop segments perfused with
ATF containing furosemide and albumin (925 34 vs. 1248
59 pEq/min; P <0.05) (Fig. 1). The addition of sulfisoxazole to
perfusates which contain furosemide but no albumin did not
increase furosemide's effect on ioop chloride reabsorption (878
87 vs. 886 65 pEq/min; P = NS).
In contrast to the results obtained with warfarin and sulfisox-
azole, addition of dansylsarcosine to ATF containing furo-
semide and albumin did not restore response to furosemide
(Fig. 2). Thus, a compound that binds to albumin at a site
different from that which binds furosemide did not alter the
inhibitory effect of albumin on furosemide response.
Chloride concentrations determined in perfusates collected
from the early distal tubule site were lower (P < 0.05) during
loop perfusion with ATF containing furosemide and albumin
than during ioop perfusion with ATF containing furosemide
alone (Fig. 3). Addition of either warfarin or sulfisoxazole to the
furosemide-albumin perfusate restored early distal tubule chlo-
ride concentration to values not different from those measured
during perfusion with furosemide alone, and significantly
greater than values measured during perfusion with furosemide
and albumin. The addition of warfarin or sulfisoxazole to ATF
containing furosemide did not affect the early distal tubule
chloride concentration. Early distal tubule chloride concentra-
tion was not different between loop segments perfused with
furosemide and albumin and loop segments perfused with a
combination of dansylsarcosine, furosemide and albumin (Fig.
4). However, both were significantly less then the group infused
only with furosemide.
The addition of 3.8 M albumin to ATF containing 60
furosemide had little effect on furosemide's ability to inhibit
loop chloride reabsorption (Fig. 5). Loop chloride reabsorption
was 655 33 pEq/min in segments perfused with ATF contain-
ing 60 tM furosemide alone, and 784 61 pEq/min in segments
Furosenijde Furosemide Furosemide Furosemide Furosemide Furosemide
+ + + + +
albumin albumin warfarin albumin sulfisoxazole
+
warfarin
+
sulfisoxazole
Fig. 1. Absolute chloride reabsorption during
loop segment perfusion with competitive
inhibitors of furosemide-albumin binding. * J <
0.05 vs. furosemide; + P < 0.05 vs. furosemide
and albumin.
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Fig. 2. Absolute chloride reabsorption during loop segment perfusion
with various combinations of furosemide, albumin and dansylsar-
cosine. Dansylsarcosine binds to albumin at a site different from that
binding furosemide. * P < 0.05 vs. furosemide.
1400
1200
1000
800
600
400
200
0
1400
1200
1000
800
600
400
200
Furosemide Furosemide Furosemide
+ +
albumin albumin
+
dansylsarcosine
422 Kirchner et a!: Albuminuria and diuretic resistance
0w
E
a)
Ui
E
Furosemide Furosemide Furosemjde
+ +
albumin albumin
+
warfarin
Furosemide Furosemide Furosemide
+ + +
warfarin albumin sulfisoxazole
+
sulfisoxazole
Fig. 3. Tubular fluid chloride concentration at
early distal tubule collection site during loop
perfusion with competitive inhibitors of
furosemide-albumin binding. * P < 0,05 vs.
furosemide, + P < 0.05 vs. furosemide and
albumin.
Furosemide Furosemide Furosemide
+ +
albumin albumin
+
dansylsarcosine
Fig. 4. Tubular fluid chloride concentration at early distal tubule
collection Site during loop perfusion with various combinations of
furosemide, albumin and dansylsarcosine. Dansylsarcosine binds to
albumin at a site different from that binding furosemide. * P < 0.05 vs.
furosemide.
perfused with ATF containing 60 sM furosemide and 3.8 M
albumin. Increasing the albumin concentration to 7.6 iM in the
60 M furosemide containing perfusate, however, significantly
impaired diuretic activity of 60 /.LM furosemide on ioop chloride
uptake. Loop chloride reabsorption was 655 33 pEq/min in
segments perfused with ATF containing 60 p.M furosemide and
1015 74 pEq/min in segments perfused with ATF containing
60 p.M furosemide with 7.6 p.M albumin (P < 0.05).
Discussion
The current study confirms that albumin in tubule fluid can
impair the loop segment response to furosemide. This study
additionally demonstrates that the extent of this impairment
depends on the relative concentrations of both agents in the
fluid entering the ioop. Thus, a greater concentration of furo-
semide reduces the inhibition produced by a constant concen-
tration of albumin. Conversely a greater concentration of albumin
60lM 60M 6OM
Furosemide Furosemide Furosemide
+
-4-
3.8 M albumin 7.6 M albumin
Fig. 5. Absolute chloride reabsorption during loop segment perfusion
with ATF containing 60 4aMfurosemide; 60 jiM furosemide and 3.8 p.M
albumin; or 60 /.LMfurosemide and 7.6 p.M albumin. *P< 0.05 vs. 60 p.M
furosemide,
impairs the loop segment response to increased concentrations
of furosemide. Furthermore, both warfarin and sulfisoxazole,
drugs which competitively inhibit binding of furosemide to
albumin in plasma, restore diuretic response in tubule fluid
containing albumin. However, neither warfarin nor sulfisox-
azole potentiates furosemide's tubular response in the absence
of albumin and warfann alone did not reduce loop chloride
reabsorption. Thus, the most plausible explanation for war-
farm's and sulfisoxazole's ability to restore furosemide re-
sponse in tubule fluid containing albumin is that these agents
displace furosemide from binding sites on albumin. This binding
appears to be a specific interaction as dansylsarcosine, a
compound which also binds to albumin but at a different site
from furosemide, failed to restore furosemide response in
tubule fluid containing albumin. Taken together, these data
argue that the reduction in furosemide response in the presence
of albumin is due to furosemide-albumin binding. The net effect
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of this interaction is a decrease in the amount of pharmacolog-
ically active drug present at the diuretic effector site in the
TALH.
A central principle in pharmacology is that binding of a drug
to protein in serum may importantly influence pharmacokinetic
and hence dynamic properties of the drug [9]. Furosemide, for
example, is highly bound to albumin in plasma (>90%) and the
extent of this binding has been demonstrated to influence the
drug's volume of distribution, total clearance and possibly its
ototoxicity [1, 2, 10, 11]. The current study indicates that
protein binding can also influence drug activity when binding
proteins gain access to biologic fluids at the drug's site of
action. Thus, the presence of albumin in ATF at a concentration
similar to that measured in the aminonucleoside induced rat
model of NS markedly attenuates the effect of furosemide on
loop chloride reabsorption. Four lines of evidence suggest this
effect results from inactivation of furosemide by binding to
albumin. First, the addition of albumin alone to ATF does not
affect loop chloride reabsorption [31. Secondly, IgG, a protein
that does not bind furosemide, has no affect on furosemide's
response [3]. Third, as indicated by the current observations,
drugs that competitively inhibit the binding of furosemide to
albumin but have no intrinsic chloruretic effect restore furo-
semide's response in albumin containing ATF. Finally, a com-
pound which binds to albumin but does not affect the binding of
furosemide fails to restore response.
The clinical significance of binding of furosemide to albumin
in the urine of patients with NS has been controversial. Green
and Mirkin first hypothesized this mechanism was responsible
for diuretic resistance in the NS [12]. Employing the aminonu-
cleoside rat model of NS they noted that the response to
furosemide was independent of serum protein concentration or
glomerular filtration rate and was inversely correlated with the
degree of proteinuria. Their findings have been disputed by
other investigators. From a comparison of sodium excretion to
total or unbound furosemide excretion rates in voided urine,
Keller and associates and Smith and coworkers concluded that
furosemide binding to filtered albumin had little effect on the
magnitude of the diuretic response and did not contribute
significantly to diuretic resistance in nephrotic individuals [1,
2]. In these latter two studies, the conclusions were based on
measurements of sodium concentration and furosemide-albu-
mm binding determined in voided urine. However, marked
alterations in sodium reabsorption occur beyond the TALH in
NS [13] and changes in ionic strength within the range encoun-
tered along the distal nephron may alter the amount of furo-
semide bound to albumin [141. Consequently, assessment of the
contribution of protein binding to the blunted diuretic response
observed in NS may be erroneous if based on data obtained in
voided urine.
The methods used in the current studies circumvent some of
the problems inherent in the prior animal and clinical investi-
gations. The microperfusion technique allows delivery of equiv-
alent concentrations of both diuretic and solute to the loop
segment in all groups of animals studied. These experimental
conditions, coupled with the observation that loop segment
fluid reabsorption was not different between groups, suggest
that the changes in chloride uptake observed in the current
study resulted from events primarily localized to the TALH.
Thus, the current study confirms that albumin in tubule fluid at
concentrations representative of those found in an animal
model of NS attenuates furosemide activity in the renal tubule.
The extent to which this mechanism contributes to the dimin-
ished diuretic response observed in nephrotic patients remains
to be determined.
Although our work to date has been confined to in vivo
microperfusion experiments in rats, the findings that displace-
ment of furosemide from albumin normalizes diuretic response
suggest potential strategies to study furosemide-protein binding
as a mechanism for diuretic resistance in man. In humans,
competitive inhibitors of drug binding to albumin in plasma
have been shown to influence the pharmacologic response to
the drug. For example, administration of sulfonamide antibiot-
ics and tolbutamide may result in hypoglycemic episodes
through this mechanism [16, 17]. Similarly, kernicterus can
occur in premature infants receiving sulfisoxazole due to dis-
placement of albumin bound bilirubin [18]. The observation that
both warfarin and sulfisoxazole restoire furosemide response in
albumin containing tubule fluid suggests that displacement
binding can have pharmacologic consequences in biologic fluids
other than plasma. It is interesting to speculate whether reduc-
ing urinary binding of furosemide to albumin might be a useful
therapeutic adjunct in nephrotic patients. Obtaining such a
benefit would presumably depend upon the urinary concentra-
tion of the inhibitor, and the relative affinities of the inhibitor
and primary drug (that is, furosemide) for albumin. Thus, while
micromolar concentrations of warfarin restore furosemide po-
tency in microperfused tubules, it is unlikely to have an effect
clinically, since negligible warfarin is excreted in the urine.
Sulfisoxazole, on the other hand, requires millimolar concen-
trations to restore furosemide's effect in vitro, but enters the
urine in high concentrations after conventional clinical doses.
Thus, if a major portion of the attenuated diuretic response
observed in NS results from furosemide binding to filtered
albumin, then studies to restore furosemide potency through
binding displacement with drugs such as sulfisoxazole seem
warranted. In fact, such studies may he the only clinical means
to quantitatively assess the contribution of binding to diuretic
resistance in this setting, since attempts to extrapolate binding
measured in final urine to the free drug concentrations present
at the TALH are subject to the caveats previously discussed.
Although our data provide compelling evidence for protein
binding contributing to diuretic resistance in NS, the results
must be considered indirect. It would have been desirable to
provide a quantitative assessment of the binding between
furosemide and albumin in our early distal tubule collectate
under the various conditions studied. Unfortunately, direct
measurement of unbound furosemide concentration in fluid
obtained from this collection site is not technically possible due
to the combination of both small sample volumes and a lack of
radiolabeled furosemide with sufficient specific radioactivity to
conduct binding measurements. Thus, while all data from this
and our previous studies [3, 14] strongly suggest that binding
between albumin and furosemide accounts for the attenuated
diuretic response observed in albumin containing perfusates
and that restoration of this response by sulfisoxazole and
warfarin is due to displacement of furosemide from albumin, the
evidence is not yet incontrovertible. Definitive data is ex-
tremely difficult to obtain with existing techniques.
In summary, the current study demonstrates that competitive
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inhibitors of furosemide-albumin binding restore the blunted
response to furosemide observed in tubule fluid which contains
albumin. In contrast, a substance which binds to albumin at a
separate location does not restore furosemide response. These
findings indicate that reductions in free furosemide concentra-
tion by binding to albumin in tubule fluid could be one mecha-
nism accounting for the blunted diuretic and natriuretic re-
sponse to ioop diuretics in NS. Future clinical assessment of the
contribution of this mechanism to overall diuretic resistance NS
can employ the principles demonstrated herein.
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